1185 / 1708
Issues with Application of
Metastatic Site RT within a global strategy
•
Why? : Survival is driven by metastatic site failure and
durability of systemic therapy is transient
Author
Rt modality Sites treated lf@rt
lf@nonRt
Gatcombe ebrt
Post
induction
1/6
Bradfield ebrt
diag
1/17
4/4
Sibley
Tbi+ebrt
Post -SCT 1/10
Polishchuck ebrt
Post
induction
3/19
128/506
Kandula
ebrt
Post
induction
3/13
Pmid :2523825;28068235;7607934;15022296;19211198